Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote & News

Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a pat...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 659 0067

Fax: 206 659 0667

Website: www.adaptivebiotech.com

Address:

1165 Eastlake Avenue East, Seattle, United States

Treasury225 Oct. 23 at 10:49 PM

$ADPT what the heck is happening after hours?

2 · Reply

Whales22 Oct. 23 at 7:25 AM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $ADPT $BTAI $DUO $CODX Watchlist..

0 · Reply

Treasury225 Oct. 22 at 2:11 PM

$ADPT would love to know the story behind the 565,000 shares that traded at 16:27 yesterday that seemed to have a carry over to this mess of an opening today. Makes me question the motives behind this mornings price target update…..

1 · Reply

JarvisFlow Oct. 22 at 12:10 PM

BTIG has updated their rating for Adaptive Biotechnologies ( $ADPT ) to Buy with a price target of 19.

0 · Reply

WallStreetBuyDip Oct. 21 at 8:02 PM

Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.

0 · Reply

WAJeff Oct. 15 at 8:09 PM

$ADPT $17.14 52 week high

0 · Reply

WAJeff Oct. 15 at 5:44 PM

More $ADPT sold at $16.50, $16.79 52 week high. This is up 175.4% ytd

0 · Reply

JarvisFlow Oct. 15 at 1:57 PM

Piper Sandler updates rating for Adaptive Biotechnologies ( $ADPT ) to Overweight, target set at 15 → 20.

0 · Reply

DARKP00L Oct. 13 at 1:20 PM

$ADPT 09:19 on Oct. 13 2025 JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $17 #tradeideas

0 · Reply

_CircuitBreaker Oct. 9 at 11:03 PM

Keep a close watch on CMCT! $TROX $OCGN $SKYE $ADPT -

1 · Reply

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Sep 10, 2025, 3:58 PM EDT - 6 weeks ago

Adaptive Biotechnologies Corporation (ADPT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 27, 2025, 4:05 PM EDT - 2 months ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 8, 2025, 6:05 AM EDT - 2 months ago

Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts

ASPS

Aug 6, 2025, 2:13 AM EDT - 2 months ago

Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Jul 15, 2025, 4:05 PM EDT - 3 months ago

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 1, 2025, 7:30 AM EDT - 4 months ago

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

May 30, 2025, 7:30 AM EDT - 5 months ago

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

May 28, 2025, 4:05 PM EDT - 5 months ago

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 1, 2025, 9:46 PM EDT - 6 months ago

Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 6 months ago

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

Apr 10, 2025, 4:05 PM EDT - 7 months ago

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 8, 2025, 8:00 AM EDT - 7 months ago

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Mar 11, 2025, 8:00 AM EDT - 8 months ago

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Feb 11, 2025, 7:47 PM EST - 9 months ago

Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 4:05 PM EST - 9 months ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 4:05 PM EST - 9 months ago

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Jan 22, 2025, 4:05 PM EST - 9 months ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Jan 14, 2025, 7:30 AM EST - 10 months ago

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Jan 7, 2025, 7:30 AM EST - 10 months ago

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Jan 2, 2025, 4:05 PM EST - 10 months ago

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 6:55 AM EST - 11 months ago

Top 3 Health Care Stocks That May Collapse This Quarter

FNA NAMS

Dec 7, 2024, 6:30 PM EST - 11 months ago

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Dec 3, 2024, 7:30 AM EST - 11 months ago

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Nov 26, 2024, 10:53 AM EST - 11 months ago

Adaptive Biotechnologies: Making Some Progress

Nov 7, 2024, 9:57 PM EST - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Oct 9, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Aug 22, 2024, 4:03 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 1, 2024, 10:25 PM EDT - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

May 31, 2024, 7:30 AM EDT - 1 year ago

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 29, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 7, 2024, 8:59 PM EDT - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 2, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

Feb 22, 2024, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Feb 14, 2024, 9:51 PM EST - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript

ANY

Feb 14, 2024, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 29, 2024, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Dec 27, 2023, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 9, 2023, 8:30 AM EST - 2 years ago

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

Dec 5, 2023, 7:30 AM EST - 2 years ago

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

Nov 9, 2023, 10:01 PM EST - 2 years ago

Adaptive Biotechnologies Corporation (ADPT) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 5:52 PM EST - 2 years ago

Adaptive Biotech hires Goldman Sachs to explore ‘strategic alternatives' for key business lines

Treasury225 Oct. 23 at 10:49 PM

$ADPT what the heck is happening after hours?

2 · Reply

Whales22 Oct. 23 at 7:25 AM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $ADPT $BTAI $DUO $CODX Watchlist..

0 · Reply

Treasury225 Oct. 22 at 2:11 PM

1 · Reply

JarvisFlow Oct. 22 at 12:10 PM

BTIG has updated their rating for Adaptive Biotechnologies ( $ADPT ) to Buy with a price target of 19.

0 · Reply

WallStreetBuyDip Oct. 21 at 8:02 PM

0 · Reply

WAJeff Oct. 15 at 8:09 PM

$ADPT $17.14 52 week high

0 · Reply

WAJeff Oct. 15 at 5:44 PM

More $ADPT sold at $16.50, $16.79 52 week high. This is up 175.4% ytd

0 · Reply

JarvisFlow Oct. 15 at 1:57 PM

Piper Sandler updates rating for Adaptive Biotechnologies ( $ADPT ) to Overweight, target set at 15 → 20.

0 · Reply

DARKP00L Oct. 13 at 1:20 PM

$ADPT 09:19 on Oct. 13 2025 JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $17 #tradeideas

0 · Reply

_CircuitBreaker Oct. 9 at 11:03 PM

Keep a close watch on CMCT! $TROX $OCGN $SKYE $ADPT -

1 · Reply

WallStreetBuyDip Oct. 9 at 7:43 PM

0 · Reply

SweepCastApp Oct. 4 at 9:38 AM

$ADPT: Unusual Options Activity Alerted CALL flow observed 70x contracts at Strike price of $12.5 Exp on 01/16/2026 with Premium of $27K and showing BULLISH Sentiment

1 · Reply

Treasury225 Oct. 2 at 2:48 PM

$ADPT looks like Guggenheim can’t support their touts.

1 · Reply

Treasury225 Sep. 30 at 8:12 PM

$ADPT WOW! Guggenheim carries some weight here!!!! So many positive technical things happening too many to mention. GREAT DAY

0 · Reply

Stella_Stone_59 Sep. 30 at 7:18 PM

$ADPT Naysayers faded .28. The chart’s answer: hold my beer—make it .30. 🍺🚀 $BNKK

0 · Reply

DARKP00L Sep. 30 at 3:27 PM

$ADPT 11:07 on Sep. 30 2025 Adaptive Biotechnologies shares are trading higher after Guggenheim initiated coverage with a Buy rating and a $20 price target. #tradeideas

0 · Reply

ChrisJohnson90 Sep. 30 at 2:53 PM

$ADPT Broooo $BNKK getting institutional LOVE 💎🙌 I’m BTFD till GAPUP $1+ 🚀🚀🌕 LFG fam!

0 · Reply

jgalfano4 Sep. 30 at 2:42 PM

$ADPT Nice chart on all 3 - Daily, Weekly, Monthly. Rounded bottom with heavy buying volume. Looks to be heading north. Monthly chart below.

0 · Reply

ChrisJohnson90 Sep. 30 at 2:40 PM

$ADPT Tiny float + DeFi pivot + funds onboard = STRG setup. Phase 1: quiet accumulation → Phase 2: PUMP. Next stop $0.60–0.80?

0 · Reply

DARKP00L Sep. 30 at 2:40 PM

$ADPT 10:16 on Sep. 30 2025 Guggenheim Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $20 #tradeideas

0 · Reply

JarvisFlow Sep. 30 at 2:16 PM

Guggenheim updates rating for Adaptive Biotechnologies ( $ADPT ) to Buy, target set at 20.

0 · Reply

notreload_ai Sep. 30 at 11:53 AM

Guggenheim rated $ADPT a "Buy." It dominates blood cancer testing and will see major growth. "Shares are currently undervalued." https://notreload.xyz/adaptive-biotechnologies-dominant-cancer-test-provider/

0 · Reply

Market Cap	2.61B
Revenue (ttm)	178.96M
Net Income (ttm)	-159.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-89.12%
Debt to Equity Ratio	0.00

Volume	1,213,700
Avg Vol	1,888,206
Day's Range	N/A - N/A
Shares Out	152.27M
Stochastic %K	75%
Beta	2.06
Analysts	Strong Sell
Price Target	$17.14